Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | HTT | P42858 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896315 | 0.84 | MAPT (0.49) | MAPTHTTLMNAKDM4ENPSR1 | |
| SCHEMBL30896312 | 0.81 | KDM4E (0.40) | MAPTHTTLMNAKDM4ENPSR1 | |
| SCHEMBL30896380 | 0.81 | ALDH1A1 (0.40) | MAPTHTTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL30896471 | 0.79 | ADORA2A (0.41) | MAPTHTTLMNAKDM4ENPSR1 | |
| SCHEMBL31613166 | 0.79 | TRPA1 (0.37) | MAPTHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL30896370 | 0.79 | SCN9A (0.38) | MAPTHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL30896396 | 0.79 | ATAD2 (0.49) | PDE3BPDE3A | |
| SCHEMBL30896317 | 0.75 | MAPK14 (0.47) | KDM4EPDE3BPDE3ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30896413 | 0.74 | TDP1 (0.38) | SMN1; SMN2ALDH1A1GAAPKML3MBTL1 | |
| SCHEMBL31613171 | 0.74 | TDP1 (0.38) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612128-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120129677-A | Compounds and their use for the treatment of heme lesions | 百时美施贵宝公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2024097932-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | MAPT 4138/4885HTT 875/4885LMNA 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.